- Home
- GPRO vs CGEN Comparison
GPRO vs CGEN Comparison
Compare GPRO & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPRO
- CGEN
- Stock Information
- Founded
- GPRO 2004
- CGEN 1993
- Country
- GPRO United States
- CGEN Israel
- Employees
- GPRO N/A
- CGEN N/A
- Industry
- GPRO Industrial Machinery/Components
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GPRO Consumer Discretionary
- CGEN Health Care
- Exchange
- GPRO Nasdaq
- CGEN Nasdaq
- Market Cap
- GPRO 118.4M
- CGEN 167.4M
- IPO Year
- GPRO 2014
- CGEN 2000
- Fundamental
- Price
- GPRO $0.76
- CGEN $1.72
- Analyst Decision
- GPRO Hold
- CGEN
- Analyst Count
- GPRO 1
- CGEN 0
- Target Price
- GPRO $1.50
- CGEN N/A
- AVG Volume (30 Days)
- GPRO 5.1M
- CGEN 177.6K
- Earning Date
- GPRO 08-05-2025
- CGEN 08-05-2025
- Dividend Yield
- GPRO N/A
- CGEN N/A
- EPS Growth
- GPRO N/A
- CGEN N/A
- EPS
- GPRO N/A
- CGEN N/A
- Revenue
- GPRO $780,312,000.00
- CGEN $27,589,000.00
- Revenue This Year
- GPRO N/A
- CGEN N/A
- Revenue Next Year
- GPRO $6.79
- CGEN $173.80
- P/E Ratio
- GPRO N/A
- CGEN N/A
- Revenue Growth
- GPRO N/A
- CGEN N/A
- 52 Week Low
- GPRO $0.40
- CGEN $1.13
- 52 Week High
- GPRO $1.76
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- GPRO 49.20
- CGEN 55.93
- Support Level
- GPRO $0.72
- CGEN $1.62
- Resistance Level
- GPRO $0.95
- CGEN $1.81
- Average True Range (ATR)
- GPRO 0.06
- CGEN 0.09
- MACD
- GPRO -0.02
- CGEN -0.00
- Stochastic Oscillator
- GPRO 30.07
- CGEN 58.63
About GPRO GoPro Inc.
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts and accessories, lifestyle gear, applications, and subscriptions and services. The company sells products across the world through retailers, distributors, and on GoPro.com. Its hardware products are designed and developed in the United States, France, China, and Romania, and a majority of the manufacturing is outsourced to contract manufacturers located in China, Thailand, and Vietnam. Geographically, the company generates maximum revenue from the Americas, followed by Europe, Middle East and Africa (EMEA), and Asia and Pacific (APAC) region.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.